anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The development of a potentially life-threatening serotonin syndrome has been reported with serotonin norepinephrine reuptake inhibitors (SNRIs) and SSRIs, including desipramine hydrochloride, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John’s Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).

Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular changes (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome.

The concomitant use of desipramine hydrochloride with MAOIs intended to treat psychiatric disorders is contraindicated. Desipramine hydrochloride should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking desipramine hydrochloride. Desipramine hydrochloride should be discontinued before initiating treatment with the MAOI (see CONTRAINDICATIONS and DOSAGE AND ADMINISTRATION).

If concomitant use of desipramine hydrochloride with other serotonergic drugs including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, and St. John’s Wort is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome particularly during treatment initiation and dose increases.

Treatment with desipramine hydrochloride and any concomitant serotonergic agents should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.
The present invention discloses a method for treating patients with liver-complaints, using EPO as the effective ingredient for reducing stored iron in liver in order to improve hepatic functions. The method of the present invention can be used to treat patients with chronic hepatitis induced by iron overload, hepatocirrhosis and hepatoma. Phlebotomy can be combined into the method of the present invention so that anemia induced by phlebotomy can be prevented and the stored iron in the liver can be reduced more effectively for the patient. Furthermore, for chronic hepatitis C patients ineffectual to conventional 1FN therapy, the method can be used to improve their hepatic functions before 1FN therapy is used to treat hepatitis C patients. In this invention, it discloses the first time that EPO can cause the stored iron to be released from liver through binding to specific receptors in liver. Iron is removed from hepatocytes by administering EPO without reducing iron throughout the body since sideropenia does not occur in the patients. Therefore, EPO can be used to improve hepatic functions for patients with chronic hepatitis, hepatocirrhosis and hepatoma.
Mild cognitive impairment (MCI) is often at high risk of progression to Alzheimer's disease (AD). Existing works to identify the progressive MCI (pMCI) typically require MCI subtype labels, pMCI vs. stable MCI (sMCI), determined by whether or not an MCI patient will progress to AD after a long follow-up. However, prospectively acquiring MCI subtype data is time-consuming and resource-intensive; the resultant small datasets could lead to severe overfitting and difficulty in extracting discriminative information. Inspired by that various longitudinal biomarkers and cognitive measurements present an ordinal pathway on AD progression, we propose a novel Hybrid-granularity Ordinal PrototypE learning (HOPE) method to characterize AD ordinal progression for MCI progression prediction. First, HOPE learns an ordinal metric space that enables progression prediction by prototype comparison. Second, HOPE leverages a novel hybrid-granularity ordinal loss to learn the ordinal nature of AD via effectively integrating instance-to-instance ordinality, instance-to-class compactness, and class-to-class separation. Third, to make the prototype learning more stable, HOPE employs an exponential moving average strategy to learn the global prototypes of NC and AD dynamically. Experimental results on the internal ADNI and the external NACC datasets demonstrate the superiority of the proposed HOPE over existing state-of-the-art methods as well as its interpretability.
This prospective, randomized, controlled study investigates the efficacy of virtual reality (VR) as a means to alleviate pain and anxiety in individuals receiving thyroid biopsies and PICC placements with local anesthesia. This study was conducted at Temple University Hospital between June 2021 and August 2022. A total of 107 patients were randomized into treatment and control groups. The VR experience involved wearing a headset with an immersive 3D visual display and accompanying music, simulating a calming environment. Patients completed Visual Analog Scales for pain and anxiety both before and after the intervention, reflecting their pain and anxiety levels prior to and during the procedure. The primary endpoints were to observe the effect of VR on pain and anxiety in both groups.
The present invention is related to the method for obtaining aggregated antigenic structures that are capable of enhancing an immune response to aggregate antigens administered systemically and/or mucosally generating powerful immune response and to the chemical structures resulting from the application of said method, to the formulations obtained from such structures and their use.   The method describes the obtention of novel aggregate antigenic structures by using aggregating, delipidating or oxidating agents or compounds enabling the release of lipids from the particles and their heterogeneous aggregation, wherein aggregates with particle sizes of between 30 and 500 nm are subsequently selected by means of a molecular exclusion process. The aggregation state can also be provoked inside the yeast by changing incubation conditions. The resulting structures can be used conveniently adjuvated or in a formulation in which several antigens can be introduced, wherein synergism between said components is found with respect to the immunogenicity of the response obtained. The preparation may also contain stabilizers and preservatives. The resulting antigenic structures can be used in the pharmaceutical industry as preventive or therapeutic vaccine formulation both for human and veterinary use and as part of diagnostic system.
BACKGROUND: Inflammation and pyroptosis have crucial impacts on the development of acute kidney injury (AKI) and have been validated in a variety of existing AKI animal models. However, the mechanisms underlying wasp venom-induced AKI are still unclear. The involvement of nucleotide-binding oligomerization domain (NOD)-like receptor protein 3 (NLRP3) in some mouse models of AKI has been extensively documented, and its crucial function in controlling inflammation and pyroptosis has been highlighted. The objective of our study was to investigate the role and mechanism of NLRP3 in inflammation and pyroptosis associated with wasp venom-induced AKI.
METHODS: A mouse model of AKI induced by wasp venom pre-injected with an NLRP3 inhibitor was used to study the role and mechanism of NLRP3. To verify the importance of NLRP3, western blotting was performed to assess the expression of NLRP3, caspase-1 p20, and gasdermin D (GSDMD)-N. Additionally, quantitative real-time polymerase was used to determine the expression of NLRP3, caspase-1, and GSDMD. Furthermore, enzyme-linked immunosorbent assay was utilized to measure the levels of interleukin (IL)-1β and IL-18.
RESULTS: NLRP3 was found to be the downstream signal of the stimulator of interferon genes in the wasp sting venom-induced AKI model. The administration of wasp venom in mice significantly upregulated the expression of NLRP3, leading to renal dysfunction, inflammation, and pyroptosis. Treatment with an NLRP3 inhibitor reversed the renal damage induced by wasp venom and attenuated pathological injury, inflammatory response, and pyroptosis.
CONCLUSION: NLRP3 activation is associated with renal failure, inflammatory response and pyroptosis in the hyper early phase of wasp venom-induced AKI. The inhibition of NLRP3 significantly weakened this phenomenon. These findings could potentially offer a viable therapeutic approach for AKI triggered by wasp venom.
Delirium, a syndrome characterized by an acute change in attention, awareness, and cognition, is commonly observed in older adults, although there are few quantitative monitoring methods in the clinical setting. We developed a bispectral electroencephalography (BSEEG) method capable of detecting delirium and can quantify the severity of delirium using a novel algorithm. Preclinical application of this novel BSEEG method can capture a delirium-like state in mice following lipopolysaccharide administration. However, its application to postoperative delirium (POD) has not yet been validated in animal experiments. This study aimed to create a POD model in mice with the BSEEG method by monitoring BSEEG scores following EEG head-mount implantation surgery and throughout the recovery. We compared the BSEEG scores of C57BL/6J young (2-3 months old) with aged (18-19 months old) male mice for quantitative evaluation of POD-like states. Postoperatively, both groups displayed increased BSEEG scores and a loss of regular diurnal changes in BSEEG scores. In young mice, BSEEG scores and regular diurnal changes recovered relatively quickly to baseline by postoperative day (PO-Day) 3. Conversely, aged mice exhibited prolonged increases in postoperative BSEEG scores and it reached steady states only after PO-Day 8. This study suggests that the BSEEG method can be utilized as a quantitative measure of POD and assess the effect of aging on recovery from POD in the preclinical model.
Patients at St. John's Rehab undergoing rehabilitation are supported by an interprofessional team - including physiatrists, nurses, occupational therapists, speech language pathologists, physical therapists, social workers and psychiatrists. During their inpatient stay, patients receive a wide range of rehabilitation services aimed at addressing their physical, emotional and cognitive care needs. Length of stay for inpatient services ranges between 2 to 12 weeks.
1452179 Steroid 3-oximes ORTHO PHARMACEUTICAL CORP 28 Feb 1974 [1 March 1973] 9169/74 Heading C2U The invention comprises compounds of formulae wherein R 1  is H or COR 2 ; R 2  is C 1-8  alkyl, phenyl, C 3-6  cycloalkyl, adamantyl or C 1-5  trihaloalkyl; R 3  is C 2-5  alkynyl, C 3-5  alkadienyl or C 3-6  cycloalkyl; R 4  is H, C 1-5  alkyl, N-(C 1-5  alkyl) carbamoyl or C 3-5  cycloalkyl; and R 5  is C 1-5  alkyl; with the proiiso that (i) in compounds I when R 1  is H or acetyl then R 4  is not H, and (ii) in compounds II when R 3  is alkynyl or alkadienyl then R 2  is not alkyl. Preparation is from the corresponding 3-ones by reaction with an appropriate hydroxylamine salt in the presence of a base, optionally followed by 17- esterification, or separation of syn and anti isomers by fractional crystallization or column chromatography. Also, ethisterone acetate oxime is converted to its o-(N-methylcarbamoyl) derivative by reaction with methyl isocyanate. The oximes of ethisterone and ethisterone acetate are separated into their syn and anti isomers by column chromatography on silica gel (Ex. III). Ethisterone is converted to its benzoate and cyclopropane-, cyclobutane-, and cyclopentanecarboxylates by reaction with the appropriate carboxylic acids in the presence of trifluoroacetic anhydride (Ex. IV). The cyclopropanecarboxylate is also prepared using cyclopropanecarbonyl chloride in refluxing benzene (Ex. 1). Oral antilittering compositions comprise a compound I and a carrier.
Safety and effectiveness of Enoxaparin Sodium Injection in pediatric patients have not been   
established.   
Enoxaparin Sodium Injection is not approved for use in neonates or infants.   
Serious adverse reactions including fatal reactions and the “gasping syndrome” occurred in premature neonates and low birth weight infants in the neonatal intensive care unit who received drugs containing benzyl alcohol as a preservative. In these cases, benzyl alcohol dosages of 99 to 234 mg/kg/day produced high levels of benzyl alcohol and its metabolites in the blood and urine (blood levels of benzyl alcohol were 0.61 to 1.378 mmol/L). Additional adverse reactions included gradual neurological deterioration, seizures, intracranial   
hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse. Preterm, low-birth weight infants may be more likely to develop these reactions because they may be less able to metabolize benzyl alcohol. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known. Enoxaparin Sodium Injection multiple-dose vials contain 15 mg/mL of benzyl alcohol (at the dose of 1.5 mg/kg twice a day, benzyl alcohol exposure in patients is 0.45 mg/kg daily) [ see Warnings and Precautions ( 5.8) ].
The patients in the video group will be shown the video of using MDI prepared by the researchers. The training will be completed by watching the MDI usage video prepared by the researchers in the patients in the video group. After the training, the patients will be asked to use the inhaler again and their skill scores will be re-evaluated. Their mistakes will be shown by making them watch it again from the video. On the 7th day of the study, the patients will be called by the researcher with a video call, and the patients will be asked to use their MDI drugs again, and the MDI use skill chart will be filled again.
NEW MATERIAL:The alpha,beta-unsaturated ketone of formula I (R<1>-R<3> are lower alkyl). EXAMPLE:5,5,8-Trimethyl-3,7-nonadien-2-one. USE:A component of a perfumery composition. It has fragrance of various floral notes such as woody note accompanied by ozone-like odor with green top-note, floral note accompanied by sweet honey-like fragrance, etc. It has strong diffusibility and lasting property of elegant and modern floral note with effectively demonstrated fragrance and is useful as a raw material of compound perfume having floral note such as muguet, rose, lilac, etc. PREPARATION:The compound of formula I can be produced by condensing a 2-substituted-5-methyl-4-hexen-1-al of formula II with nearly equivalent or excess amount of a ketone of formula III optionally in a solvent in the presence of a base such as KOH at -70-+150 deg.C.
Computer system (100) and method for index creation in a streaming database (130) with medical state parameters of different types associated with a plurality of patients (10) is provided to allow near-real-time access to medical state parameters reflecting medical states of patients. A message broker (110) receives messages in one or more incoming data streams (30). The messages include records with current measured medical state parameter values (11-1) of patients. A stream processor (120) processes incoming messages with a plurality of parameter augmentation algorithms (PAA1 to PAAn) wherein each parameter augmentation algorithm is adapted to derive additional computed medical state parameter values for the respective patient. Records with the computed values are then inserted via generated messages (mg<sup>∗</sup>) into any incoming data stream. A data handler (140) can create persisted patient-signal specific stream data tables for yet unknown combinations of patient identifier and signal identifier in the streaming database (130), and can further create a block range index for the time information of said persisted stream data table. Records contained in the received and generated messages (m<sup>∗</sup>, mg<sup>∗</sup>) are then written into respective persisted patient-signal specific stream data tables (SDT-P2-S1 to SDT-P2-Sn) of the streaming database (130), and the respective block range indexes are updated accordingly upon record insertion.
Several modifiable lifestyle risk factors have been linked to higher cancer risk in the literature. Determining the proportion and number of cancer cases attributable to these risk factors is pivotal in informing effective cancer prevention and control plans that have the greatest effect on reducing cancer incidence. We aimed to estimate the proportion and number of incident cancer cases that were attributable to modifiable lifestyle risk factors (ie, tobacco smoking, high alcohol consumption, excess body weight, physical inactivity and unhealthy diet) in Switzerland between 2015 and 2019. The exposure prevalence of selected risk factors was estimated based on the representative national nutrition survey menuCH, the associated relative risks were obtained from systematic literature reviews and the numbers of incident cancer cases were provided by the National Institute for Cancer Epidemiology and Registration. The fractions and numbers of attributable cases were calculated overall, by sex and by the three major language regions of Switzerland. The investigated modifiable risk factors combined were linked to 25.2% of potentially preventable incident cancer cases in Switzerland between 2015 and 2019. The proportion and numbers were slightly larger in males (28.4%, 6945 cases per year) than in females (21.9%, 4493 cases per year), and variations were observed between language regions. Tobacco smoking, excess body weight and high alcohol consumption were the leading contributors to lifestyle-attributable cancer cases. The observed differences in the leading risk factors both within Switzerland and compared to other countries underline the need for regionally and nationally tailored cancer prevention and education strategies.
FIELD: biotechnology, pharmacy. SUBSTANCE: invention relates to liposome preparations. Method of making liposomes (diameter is 0.1-50 mcm) exhibiting monolayer or multilayer structure and containing water-insoluble or undissolved materials consisting of particles involves: (a) making liposomes and total removal of organic solvent used in preparing process; (b) lyophilization of prepared liposomes and (c) rehydration of liposomes in solid mixture with particle-containing material. Preferably incapsulated materials are particle-containing materials being the most preferable materials are microorganisms, plant and animal cells or nondissolved structures showing nonstable biochemical or immunological activity in organic solvent. Also, any water-insoluble particle can be incapsulated by the method given. For example, catalysts or drugs that are difficultly soluble in water can be incapsulated also. This ensures to provide prolonged-release of active component in patient body without use of detergents that are used in liposome preparing procedures. EFFECT: improved method of liposome producing. 37 cl, 1 tbl, 8 dwg, 3 ex
Administer olopatadine hydrochloride nasal spray by the nasal route only.

Priming: Before initial use, prime olopatadine hydrochloride nasal spray by releasing 5 sprays or until a fine mist appears. The correct amount of medication cannot be assured before the initial priming.

Re-priming (as needed): When olopatadine hydrochloride nasal spray has not been used for more than 7 days, re-prime by releasing 2 sprays. Avoid spraying olopatadine hydrochloride nasal spray into the eyes.

Discard Instructions: Discard nasal device after 240 sprays (enough for 30 days of dosing) have been used even though the bottle is not completely empty. The correct amount of medication cannot be assured after 240 sprays have been used.
An acupuncture physician will administer acupuncture at 6-12 acupoints in the upper and middle trapezius area (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels). Cervical Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise (rotation) as needed.
The aim of the study of examine the effect of video-assisted instruction on Type 2 diabetes patients' insulin treatment self-management and insulin administration skills. The research will be conducted as a single group pre-test post-test quasi-experimental study. The sample of the study will be consisted of 50 patients with Type 2 Diabetes. Before the training, the patients will be self-injected a dose of insulin. After giving verbal training, the patients will watch a video recording of insulin treatment and administration. The author will be evaluated the patients' insulin treatment self-management and insulin administration skills after the training.
BACKGROUND: Lowering the exit position of the tibial tunnel can improve the clinical efficacy of posterior cruciate ligament (PCL) reconstruction, however, there is no unified positioning standard. This study aimed to use novel soft tissue landmarks to create a low tunnel.
METHODS: A total of 14 human cadaveric knees and 12 patients with PCL injury were included in this study. Firstly, we observed the anatomical position between the PCL, posterior septum, and other tissue, and evaluated the relationship between the center of the low tibial tunnel (SP tunnel) and posterior septum and distal reflection of posterior capsule, and using computed tomography (CT) to evaluate distance between the center of the SP tunnel with bony landmarks. Then, evaluated the blood vessels content in the posterior septum with HE staining. Finally, observed the posterior septum and distal reflection of the posterior capsule under arthroscopy to explore the clinical feasibility of creating a low tibial tunnel, and assessed the risk of surgery by using ultrasound to detect the distance between the popliteal artery and the posterior edge of tibial plateau bone cortex.
RESULTS: In all 14 cadaveric specimens, the PCL tibial insertions were located completely within the posterior medial compartment of the knee. The distance between the center of the SP tunnel and the the articular surface of tibial plateau was 9.4 ± 0.4 mm. All SP tunnels retained an intact posterior wall, which was 1.6 ± 0.3 mm from the distal reflection of the posterior capsule. The distances between the center of the SP tunnel and the the articular surface of tibial plateau, the champagne glass drop-off were 9.2 ± 0.4 mm (ICC: 0.932, 95%CI 0.806-0.978) and 1.5 ± 0.2 mm (ICC:0.925, 95%CI 0.788-0.975) in CT image. Compared with the posterior capsule, the posterior septum contained more vascular structures. Last, all 12 patients successfully established low tibial tunnels under arthroscopy, and the distance between the posterior edge of tibial plateau bone cortex and the popliteal artery was 7.8 ± 0.3, 9.4 ± 0.4 and 7.4 ± 0.3 mm at 30°, 60° and 90° flexion angels after filling with water and supporting with shaver in posterior-medial compartment of knee joint.
CONCLUSIONS: A modified low tibial tunnel could be established in the PCL anatomical footprint by using the posterior septum and posterior capsule as landmarks.